Christian Mangala, Rolf Moukanda-Ifoundou, Denis Maulot-Bangola, Alain Moutsinga, Christian Mombo-Maganga, Serge Christian Okolongo-Mayani, Brice Ongali, Guy Joseph Lemamy, Rachyda Massolou-Outata
{"title":"Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon.","authors":"Christian Mangala, Rolf Moukanda-Ifoundou, Denis Maulot-Bangola, Alain Moutsinga, Christian Mombo-Maganga, Serge Christian Okolongo-Mayani, Brice Ongali, Guy Joseph Lemamy, Rachyda Massolou-Outata","doi":"10.1186/s12981-025-00744-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment. This study aimed to determine the effectiveness rate of dolutegravir-based treatment among HIV/AIDS patients.</p><p><strong>Methods: </strong>A retrospective observational study was conducted among HIV/AIDS patients who started antiretroviral treatment since 48 weeks of follow-up.</p><p><strong>Results: </strong>The effectiveness rate of dolutegravir-based treatment was 85.1%. HIV/AIDS patients with a CD4 + count below 200 cel/mm<sup>3</sup>, singles, and HIV/AIDS patients whose treatment duration exceeded 12 months were at risk and likely to have an active infection (P = 0.0001).</p><p><strong>Conclusion: </strong>Dolutegravir-based treatment remains effective among HIV/AIDS patients treated at the Nkembo Outpatient Treatment Center.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":"50"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12981-025-00744-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment. This study aimed to determine the effectiveness rate of dolutegravir-based treatment among HIV/AIDS patients.
Methods: A retrospective observational study was conducted among HIV/AIDS patients who started antiretroviral treatment since 48 weeks of follow-up.
Results: The effectiveness rate of dolutegravir-based treatment was 85.1%. HIV/AIDS patients with a CD4 + count below 200 cel/mm3, singles, and HIV/AIDS patients whose treatment duration exceeded 12 months were at risk and likely to have an active infection (P = 0.0001).
Conclusion: Dolutegravir-based treatment remains effective among HIV/AIDS patients treated at the Nkembo Outpatient Treatment Center.
期刊介绍：
AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
